Haleon announces Q3 2026 organic revenue growth of 2.6%
The company reports strong Oral Health performance, updates FY26 guidance, and allocates a further £500m for share buybacks despite softness in respiratory categories.
See the latest news and media coverage for Haleon. We track all announcements, press releases, and industry mentions in real time, all in one place.
Consumer health company
haleon.comLast updated
In short: Haleon reported H1 results with a higher dividend, £175m India investment, debt refinancing, and completed buyback.
The company reports strong Oral Health performance, updates FY26 guidance, and allocates a further £500m for share buybacks despite softness in respiratory categories.
The firm completed a two billion dollar buyback of senior notes maturing in March 2027 through its subsidiary. Additional financial specifics appear in official regulatory filings.
The net proceeds will fund the repurchase of existing senior notes due in March 2027 and support general corporate purposes.
The company declared a 9% increased interim dividend of 2.4 pence per share. An analysts' presentation is available via webcast on July 30, 2026.
Haleon became the latest consumer goods group to blame weaker demand for cough, cold and flu medicines for lacklustre sales, cutting its annual revenue growth...
Haleon plc (LSE/NYSE: HLN), the consumer health leader behind well-known brands such as Sensodyne, Panadol, and Centrum, has issued its Q3 trading update for the...
Oct 6 (Reuters) - British drugmaker GSK GSK.L on Friday said it raised 885.6 million pounds ($1.08 billion) from a stake sale in Haleon HLN.L...
The facility to make oral-health products in Madhya Pradesh is the largest plant the company has taken on.
Track Haleon and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Haleon and other trending companies.